🚀 VC round data is live in beta, check it out!
Revolution Medicines Valuation Multiples
Discover revenue and EBITDA valuation multiples for Revolution Medicines and similar public comparables like Innovent Biologics, Incyte, Shionogi, Sichuan Biokin and more.
Revolution Medicines Overview
About Revolution Medicines
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.
Founded
2014
HQ
Employees
883
Website
Sectors
Financials (LTM)
EV
$17B
Revolution Medicines Financials
Revolution Medicines reported last 12-month revenue of $15M and negative EBITDA of ($1B).
In the same LTM period, Revolution Medicines generated $14M in gross profit, ($1B) in EBITDA losses, and had net loss of ($1B).
Revenue (LTM)
Revolution Medicines P&L
In the most recent fiscal year, Revolution Medicines reported revenue of — and EBITDA of ($1B).
Revolution Medicines expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $15M | XXX | — | XXX | XXX | XXX |
| Gross Profit | $14M | XXX | — | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | — | XXX | XXX | XXX |
| EBITDA | ($1B) | XXX | ($1B) | XXX | XXX | XXX |
| EBITDA Margin | (8679%) | XXX | — | XXX | XXX | XXX |
| EBIT Margin | (8662%) | XXX | — | XXX | XXX | XXX |
| Net Profit | ($1B) | XXX | ($1B) | XXX | XXX | XXX |
| Net Margin | (8336%) | XXX | — | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
Revolution Medicines Stock Performance
Revolution Medicines has current market cap of $19B, and enterprise value of $17B.
Market Cap Evolution
Revolution Medicines' stock price is $96.13.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17B | $19B | -0.6% | XXX | XXX | XXX | $-5.71 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialRevolution Medicines Valuation Multiples
Revolution Medicines trades at 1153.2x EV/Revenue multiple, and (13.3x) EV/EBITDA.
EV / Revenue (LTM)
Revolution Medicines Financial Valuation Multiples
As of April 11, 2026, Revolution Medicines has market cap of $19B and EV of $17B.
Equity research analysts estimate Revolution Medicines' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Revolution Medicines has a P/E ratio of (15.3x).
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $19B | XXX | $19B | XXX | XXX | XXX |
| EV (current) | $17B | XXX | $17B | XXX | XXX | XXX |
| EV/Revenue | 1153.2x | XXX | — | XXX | XXX | XXX |
| EV/EBITDA | (13.3x) | XXX | (15.8x) | XXX | XXX | XXX |
| EV/EBIT | (13.3x) | XXX | (14.5x) | XXX | XXX | XXX |
| EV/Gross Profit | 1222.9x | XXX | — | XXX | XXX | XXX |
| P/E | (15.3x) | XXX | (16.8x) | XXX | XXX | XXX |
| EV/FCF | (15.6x) | XXX | (18.8x) | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Revolution Medicines Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
Revolution Medicines Margins & Growth Rates
Revolution Medicines' revenue in the last 12 month grew by 853%.
Revolution Medicines' revenue per employee in the last FY averaged $0.0M, while opex per employee averaged $1.3M for the same period.
Revolution Medicines Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 853% | XXX | (100%) | XXX | XXX | XXX |
| EBITDA Margin | (8679%) | XXX | — | XXX | XXX | XXX |
| EBITDA Growth | 21% | XXX | 47% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $0.0M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $1.3M | XXX | XXX | XXX |
| G&A Expenses to Revenue | 1536% | XXX | — | XXX | XXX | XXX |
| R&D Expenses to Revenue | 7221% | XXX | — | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Revolution Medicines Public Comps
See public comps and valuation multiples for other Biopharmaceuticals comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| Innovent Biologics | XXX | XXX | XXX | XXX | XXX | XXX |
| Incyte | XXX | XXX | XXX | XXX | XXX | XXX |
| Shionogi | XXX | XXX | XXX | XXX | XXX | XXX |
| Sichuan Biokin | XXX | XXX | XXX | XXX | XXX | XXX |
| Moderna | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Revolution Medicines M&A Activity
Revolution Medicines acquired XXX companies to date.
Last acquisition by Revolution Medicines was on XXXXXXXX, XXXXX. Revolution Medicines acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by Revolution Medicines
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialRevolution Medicines Investment Activity
Revolution Medicines invested in XXX companies to date.
Revolution Medicines made its latest investment on XXXXXXXX, XXXXX. Revolution Medicines invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by Revolution Medicines
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Revolution Medicines
| When was Revolution Medicines founded? | Revolution Medicines was founded in 2014. |
| Where is Revolution Medicines headquartered? | Revolution Medicines is headquartered in United States. |
| How many employees does Revolution Medicines have? | As of today, Revolution Medicines has over 883 employees. |
| Who is the CEO of Revolution Medicines? | Revolution Medicines' CEO is Mark A. Goldsmith. |
| Is Revolution Medicines publicly listed? | Yes, Revolution Medicines is a public company listed on Nasdaq. |
| What is the stock symbol of Revolution Medicines? | Revolution Medicines trades under RVMD ticker. |
| When did Revolution Medicines go public? | Revolution Medicines went public in 2020. |
| Who are competitors of Revolution Medicines? | Revolution Medicines main competitors are Innovent Biologics, Incyte, Shionogi, Sichuan Biokin. |
| What is the current market cap of Revolution Medicines? | Revolution Medicines' current market cap is $19B. |
| What is the current revenue of Revolution Medicines? | Revolution Medicines' last 12 months revenue is $15M. |
| What is the current revenue growth of Revolution Medicines? | Revolution Medicines revenue growth (NTM/LTM) is 853%. |
| What is the current EV/Revenue multiple of Revolution Medicines? | Current revenue multiple of Revolution Medicines is 1153.2x. |
| Is Revolution Medicines profitable? | No, Revolution Medicines is not profitable. |
| What is the current EBITDA of Revolution Medicines? | Revolution Medicines has negative EBITDA and is not profitable. |
| What is Revolution Medicines' EBITDA margin? | Revolution Medicines' last 12 months EBITDA margin is (8679%). |
| What is the current EV/EBITDA multiple of Revolution Medicines? | Current EBITDA multiple of Revolution Medicines is (13.3x). |
| What is the current FCF of Revolution Medicines? | Revolution Medicines' last 12 months FCF is ($1B). |
| What is Revolution Medicines' FCF margin? | Revolution Medicines' last 12 months FCF margin is (7408%). |
| What is the current EV/FCF multiple of Revolution Medicines? | Current FCF multiple of Revolution Medicines is (15.6x). |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.